Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
| Protocol No. | PHO-COG-ANHL2121 | Scope | National |
|---|---|---|---|
| Principal Investigator | Ross, Anthony | Treatment Type | Treatment |
| Age Group | Adults and Children | Phase | Phase II |
PHO-COG-ANHL2121
Contact information
Peyton Bohle BS
webbpe@iu.edu
